Article
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2014
Rizos Helen, Menzies Alexander M, Pupo Gulietta M, Carlino Matteo S, Fung Carina, Hyman Jessica, Haydu Lauren E, Mijatov Branka, Becker Therese M, Boyd Suzanah C, Howle Julie, Saw Robyn, Thompson John F, Kefford Richard F, Scolyer Richard A, Long Georgina V
Abstract excerpt
PURPOSE: Multiple BRAF inhibitor resistance mechanisms have been described, however, their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma. EXPERIMENTAL DESIGN: Fifty-nine BRAF(V600)-mutant melanoma metastases from patients treated with dabrafenib or vemurafenib were analyzed. The genetic profile of resistance mechanisms and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.